Format

Send to

Choose Destination
Nat Rev Urol. 2015 Mar;12(3):137-44. doi: 10.1038/nrurol.2015.13. Epub 2015 Feb 10.

Are androgen receptor variants a substitute for the full-length receptor?

Author information

1
Department of Urology, First Hospital of Jilin University, 71 Xinmin Street, Changchun 130021, China.
2
Department of Urology, Mayo Clinic, 200 First Street SW Rochester, MN 55905, USA.
3
Department of Biochemistry and Molecular Biology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.

Abstract

Androgen receptor splice variants (AR-Vs)--which are expressed in castration-resistant prostate cancer (CRPC) cell lines and clinical samples--lack the C-terminal ligand-binding domain and are constitutively active. AR-Vs are, therefore, resistant to traditional androgen deprivation therapy (ADT). AR-Vs are induced by several mechanisms, including ADT, and might contribute to the progression of CRPC and resistance to ADT. AR-Vs could represent a novel therapeutic target for prostate cancer, especially in CRPC.

PMID:
25666893
DOI:
10.1038/nrurol.2015.13
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center